The Female Health Company Announces the Launch of Its FC2 Female Condom Online Training Program
CHICAGO, March 19, 2012 /PRNewswire/ -- The Female Health Company (NASDAQ: FHCO) announced today that it has officially launched a free, interactive FC2 Online Training Program for health care providers. Since the U.S. introduction of the FC2 Female Condom® in 2009, the Company has conducted "in-person" trainings across the country to raise awareness of the FC2 Female Condom, the only FDA approved, female-initiated method to prevent both sexually transmitted infections (including HIV/AIDS) and unintended pregnancy.
Rebecca Bouck, the Company's U.S. Program Manager, noted that, "Training and education are key elements to increase product awareness and usage. Clinics country-wide want and need FC2 training for their staff, which is now conveniently available online."
The online training program has been proven to be an effective tool throughout a pre-launch trial period during which more than 300 participants were successfully trained. The online training program is intended to give "frontline" health care service providers immediate access to FC2 Female Condom training. The training course consists of five modules, which employ various effective training activities derived from the Company's years of educational training.
"Initially available in English, our online training will be adapted, as needed, for global audiences and translated into additional languages, most likely French, Portuguese and Spanish, for use throughout the world," adds Lucie van Mens, FHC's Director of Program Development and SUPPORT.
To access the FC2 Online Training Program and/or to learn more, please visit: www.fc2training.com .
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and in about 130 other countries globally. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in the U.S., the European Union, Canada, Australia, South Africa, Japan, The People's Republic of China, Spain, Mexico, Greece, Turkey and the African Regional Intellectual Property Organization (ARIPO), which includes Botswana, The Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Somalia, Sudan, Swaziland, Uganda, United Republic of Tanzania, Zambia and Zimbabwe. FC2 patent applications are pending in various countries. The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.
For more information about The Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com .
SOURCE The Female Health Company
More by this Source
The Female Health Company Reports Fourth Quarter and FY2013 Operating Results
Dec 03, 2013, 08:30 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.